12.08

1.63% -0.22

Promis Neurosciences Inc (PMN)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$12.30

Offen:

$12.0062

24-Stunden-Volumen:

22,022

Relative Volume:

0.13

Marktkapitalisierung:

$108.51M

Einnahmen:

Nettoeinkommen (Verlust:

$-39.72M

KGV:

-0.6581

EPS:

-18.3554

Netto-Cashflow:

$-28.18M

1W Leistung:

-3.20%

1M Leistung:

-39.98%

6M Leistung:

+3.73%

1J Leistung:

-21.17%

1-Tages-Spanne:

$11.80

$12.63

1-Wochen-Bereich:

$11.88

$13.80

52-Wochen-Spanne:

$6.27

$39.75

Promis Neurosciences Inc Stock (PMN) Company Profile

Firmenname

Promis Neurosciences Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (621)

Telefon

416-847-6898

Adresse

SUITE 200, 1920 YONGE STREET, TORONTO

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-03-30

Neueste SEC-Einreichungen

PMN's Discussions on Twitter

Compare PMN vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PMN Promis Neurosciences Inc	12.10	110.30M	0	-39.72M	-28.18M	-18.36
VRTX Vertex Pharmaceuticals Inc	441.17	112.35B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.34	79.71B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.10	52.29B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	327.31	44.48B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	320.58	35.51B	5.36B	287.73M	924.18M	2.5229

Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten

Apr 15, 2026

ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN

Apr 15, 2026

Apr 13, 2026

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference - TradingView — Track All Markets

Apr 13, 2026

Winners Losers: Is ProMIS Neurosciences Inc stock a hidden gem2026 Breakouts & Breakdowns & Weekly High Return Forecasts - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill

Apr 10, 2026

Apr 09, 2026

Major holders and board changes in ProMIS Neurosciences (PMN) 2026 proxy statement - Stock Titan

Apr 09, 2026

Multiple System Atrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approvals By Delveinsight Neuramedy, Promis Neurosciences, Enterin Inc., Nippon Chemiphar - Mena FN

Apr 09, 2026

Apr 08, 2026

PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Can ProMIS Neurosciences Inc continue delivering strong returns2026 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn

Apr 08, 2026

Analysis Recap: Can ProMIS Neurosciences Inc continue delivering strong returnsQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Janus Henderson (PMN) discloses 14.4% holding in PROMIS Neurosciences - Stock Titan

Apr 07, 2026

Apr 04, 2026

PMN Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Promis Neurosciences (NASDAQ:PMN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Apr 04, 2026

Mar 31, 2026

Weekly Earnings: Will ProMIS Neurosciences Inc stock go up in YEARShare Buyback & Low Drawdown Investment Strategies - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Aug Volume: How does ProMIS Neurosciences Inc perform in inflationary periods2026 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn

Mar 30, 2026

Mar 27, 2026

ProMIS Neurosciences Inc expected to post a loss of $1.91 a shareEarnings Preview - TradingView — Track All Markets

Mar 27, 2026

[EFFECT] ProMIS Neurosciences Inc. SEC Filing - Stock Titan

Mar 27, 2026

Mar 26, 2026

Aug Mood: How cyclical is ProMIS Neurosciences Incs revenue stream2026 Institutional Moves & Low Risk Profit Maximizing Plans - baoquankhu1.vn

Mar 26, 2026

ProMIS Neurosciences 2025 Annual Report: Pipeline, Risks, and Strategic Objectives for Alzheimer’s Drug Development - Minichart

Mar 26, 2026

Mar 25, 2026

ProMIS Neurosciences (PMN) files $50M at-the-market sales supplement - Stock Titan

Mar 25, 2026

ProMIS Neurosciences 10-K: $0 Revenue, ($22.61) EPS, Net Loss $39.72M - TradingView

Mar 25, 2026

Alzheimer’s antibody lead and ALS programs at ProMIS (NASDAQ: PMN) - Stock Titan

Mar 25, 2026

ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 25, 2026

ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026 - TradingView

Mar 25, 2026

Heavy 2025 loss but big AD bet for ProMIS Neurosciences (PMN) with $175M funding - Stock Titan

Mar 25, 2026

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights - ChartMill

Mar 25, 2026

Mar 23, 2026

Promis Neurosciences (PMN) to Release Earnings on Monday - Defense World

Mar 23, 2026

Mar 22, 2026

How does ProMIS Neurosciences Inc perform in inflationary periods2026 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn

Mar 22, 2026

If You Invested $1,000 in Promis Neuroscie (PMN) - Stock Titan

Mar 22, 2026

Mar 20, 2026

Activity Recap: How cyclical is ProMIS Neurosciences Incs revenue streamDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn

Mar 20, 2026

Mar 18, 2026

ProMIS Neurosciences (PMN) registers 13.83M shares after $75.5M private placement - Stock Titan

Mar 18, 2026

Wellington holds 9.99% of ProMIS Neurosciences (NASDAQ: PMN) via shares and warrants - Stock Titan

Mar 18, 2026

ProMIS Neurosciences to Present Data on ALS & Parkinsons - GlobeNewswire

Mar 18, 2026

Mar 17, 2026